Brepocitinib is a first-in-class, oral, selective TKI2/JAK1 inhibitor developed by for treating severe autoimmune diseases.
It has demonstrated significant efficacy in Phase 3 trials (VALOR) for dermatomyositis reducing skin/muscle disease and enabling steroid-sparing.
Mechanism of Action: As a dual inhibitor of Tyrosine Kinase 2 (TYK2) and Janus Kinase 1 (JAK1), it blocks cytokine signaling—including type I/II interferons and IL-6—which drives inflammation in autoimmune conditions.
Targeted Conditions: Dermatomyositis (DM): Non-infectious Uveitis (NIU) Cutaneous Sarcoidosis (CS) Lichen Planopilaris (LPP)
Clinical Trial Results for dermatmyositis (VALOR): The 30 mg daily dose showed superior, rapid (by week 4) improvement in muscle and skin symptoms compared to placebo, with 62% of patients tapering steroids successfully.
In adults with dematomyositis resistant to previous therapy, the use of Brepocitinib (a TKI_JAK1 inhibitor) resulted in significant benefits with respect to myositis index, skin, disease, severity, glucocorticoid, taping, and functional disability.
Safety Profile: While serious infections were more frequent in the treatment group, they were managed; the overall safety profile was consistent with approved JAK/TYK2 inhibitors.
is a first-in-class, oral, selective TKI2/JAK1 inhibitor developed by for treating severe autoimmune diseases.
It has demonstrated significant efficacy in Phase 3 trials (VALOR) for dermatomyositis reducing skin/muscle disease and enabling steroid-sparing.
Mechanism of Action: As a dual inhibitor of Tyrosine Kinase 2 (TYK2) and Janus Kinase 1 (JAK1), it blocks cytokine signaling—including type I/II interferons and IL-6—which drives inflammation in autoimmune conditions.
Targeted Conditions: Dermatomyositis (DM): Non-infectious Uveitis (NIU) Cutaneous Sarcoidosis (CS) Lichen Planopilaris (LPP)
Clinical Trial Results for dermatmyositis (VALOR): The 30 mg daily dose showed superior, rapid (by week 4) improvement in muscle and skin symptoms compared to placebo, with 62% of patients tapering steroids successfully.
In adults with dematomyositis resistant to previous therapy, the use of Brepocitinib (a TKI_JAK1 inhibitor) resulted in significant benefits with respect to myositis index, skin, disease, severity, glucocorticoid, taping, and functional disability.
Safety Profile: While serious infections were more frequent in the treatment group, they were managed; the overall safety profile was consistent with approved JAK/TYK2 inhibitors.